Agonists that enhanced binding of integrin-expressing cells to integrin receptors

Patent metadata

Field	Value
Publication number	US-10071980-B2
Application number	US-201514751431-A
Country	US
Kind code	B2
Filing date	Jun 26, 2015
Priority date	Nov 16, 2010
Publication date	Sep 11, 2018
Grant date	Sep 11, 2018

Abstract

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

First claim

What is claimed:

1. A chemical compound having the general formula (I)

wherein
R 1 is -substituted phenyl, or a substituted or unsubstituted thienyl, furyl, pyridyl thiazolyl, oxazolyl, isoxazolyl, or pyrrolyl,
R 2 is aralkyl,
M 1 is CH 2 ,
M 2 is CO,
M 3 is absent or is O or CH 2 ,
M 4 is absent or is CH 2 ,
M 5 is absent or is O or (CR 11 R 12 ),
R 11 , when present, is hydrogen,
R 12 , when present, is hydrogen,
M 6 is selected from the group consisting of (CH 2 ) q , (CH 2 ) q -arylene-(CH 2 ) r and (CH 2 CH 2 O) q , wherein q and r are independently integers from 0 to 6,
R 3 is CONR 13 R 14 ,
R 13 , is aralkyl;
R 14 , is selected from the group consisting of hydrogen, alkyl, and aralkyl;
and
R 1 when present, may be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, azido, haloalkoxy halo, haloalkyl, amino, alkylamino, and dialkylamino,
R 2 , when present, may be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, azido, haloalkoxy-halo, haloalkyl, amino, alkylamino, and dialkylamino,
R 13 , when present, may be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, azido, haloalkoxy halo, haloalkyl, amino, alkylamino, and dialkylamino, and
R 14 , when present, may be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, hydroxy, alkoxy, azido, haloalkoxy haloalkyl, amino, alkylamino, and dialkylamino.

2. A compound selected from the group consisting of N,N,N′,N′-tetrakis(2-thienylmethyl)pentanediamide; N-(3-methoxybenzyl)-N,N′,N′-tris(2-thienylmethyl)pentanediamide; N,N,N′-tris(2-thienylmethyl)pentanediamide; N′-[2-(2-thienyl)ethyl]-N,N-bis(2-thienylmethyl)pentanediamide; N-[2-(2-thienyl)ethyl]-N,N′,N′-tris(2-thienylmethyl)pentanediamide; N,N-bis(pyridin-4-ylmethyl)-N′,N′-bis(2-thienylmethyl)pentanediamide; N,N-bis(pyridin-3-ylmethyl)-N′,N′-bis(2-thienylmethyl)pentanediamide; N,N-bis(3-methoxybenzyl)-N′,N′-bis(2-thienylmethyl)pentanediamide; N,N,N′,N′-tetrakis(4-methoxybenzyl)pentanediamide; N,N,N′,N′-tetrakis(2-thienylmethyl)hexanediamide; N,N,N′,N′-tetrakis(4-methoxybenzyl)hexanediamide; N,N,N′,N′-tetrakis(3-methoxybenzyl)hexanediamide; N,N,N′,N′-tetrakis(2-thienylmethyl)heptanediamide; 2,2′-(1,3-phenylene)bis[N,N-bis(2-thienylmethyl)acetamide]; N,N,N′,N′-tetrakis(4-methoxybenzyl)heptanediamide; N,N,N′,N′-tetrakis(2-thienylmethyl)octanediamide; (3E)-N,N,N′,N′-tetrakis(2-thienylmethyl)hex-3-enediamide; 2,2′-oxybis[N,N-bis(2-thienylmethyl)acetamide]; 3-oxo-1-(2-thienyl)-2-(2-thienylmethyl)-4,7,10-trioxa-2-azadodecan-12-yl bis(2-thienylmethyl)carbamate; N,N,N′,N′-tetrakis(4-methoxybenzyl)succinamide; ethane-1,2-diyl bis[bis(2-thienylmethyl)carbamate]; N,N,N′,N′-tetrakis(4-methoxybenzyl)octanediamide; N,N,N′,N′-tetrakis(2-thienylmethyl)pyridine-3,5-dicarboxamide; N,N,N′,N′-tetrakis(2-thienylmethyl)pyridine-2,6-dicarboxamide; N,N,N′,N′-tetrakis(2-thienylmethyl)pyridine-2,4-dicarboxamide; 2,2′-(1,4-phenylene)bis[N,N-bis(2-thienylmethyl)acetamide]; N,N′-bis(4-methoxybenzyl)-N,N′-bis(2-thienylmethyl)hexanediamide; and tert-butyl {(2S)-1,6-bis[bis(2-thienylmethyl)amino]-1,6-dioxohexan-2-yl}carbamate.

3. A pharmaceutical composition comprising:
a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.

Assignees

• Texas Heart Inst

Inventors

• Biediger Ronald J
• Market Robert V

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07C311/08

  having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring · CPC title

• A61K35/51

  Umbilical cord; Umbilical cord blood; Umbilical stem cells · CPC title

• C07D333/24

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D333/20 Primary

  by nitrogen atoms (nitro, nitroso radicals C07D333/12) · CPC title